Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Escalon MedicalESMC 34 Return-on-Tangible-Asset is 152.07% as of Mar. 2026. GuruFocus rates ESMC with a GF Score™ of 34/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Escalon Medical ranks better than 98.6% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Escalon Medical's annualizedNet Income for the quarter that ended in Mar. 2026 was $9.49 Mil. Escalon Medical's average total tangible assets for the quarter that ended in Mar. 2026 was $6.24 Mil. Therefore, Escalon Medical's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 152.07%.
The historical rank and industry rank for Escalon Medical's Return-on-Tangible-Asset or its related term are showing as below:
ESMC'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -22.07 Med: -1.72 Max: 34.05
Current: 34.05
During the past 13 years, Escalon Medical's highest Return-on-Tangible-Asset was 34.05%. The lowest was -22.07%. And the median was -1.72%.
ESMC's Return-on-Tangible-Asset is ranked better than 98.6% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.62
vs ESMC: 34.05
Escalon Medical (OTCPK:ESMC) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Escalon Medical Return-on-Tangible-Asset Related Terms
Escalon Medical Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Escalon Medical's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ESMC vs RBOT, NUWE, NUMD: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Escalon Medical's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Escalon Medical Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Escalon Medical's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Escalon Medical's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 152.07% mean?
Escalon Medical (ESMC) has a Return-on-Tangible-Asset of 152.07% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Escalon Medical and its competitors. According to the industry distribution chart, Escalon Medical ranks #12 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 1.4%.
Is Escalon Medical's Return-on-Tangible-Asset too high?
Escalon Medical's current Return-on-Tangible-Asset is 152.07%. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.62. Escalon Medical's value of 152.07% is 24427.4% above this industry median. Based on the distribution chart, Escalon Medical ranks #12 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Escalon Medical has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Escalon Medical's Return-on-Tangible-Asset compare to RBOT and NUWE?
According to the Medical Devices & Instruments industry distribution chart, Escalon Medical ranks #12 out of 855 companies for Return-on-Tangible-Asset. This places Escalon Medical in the top 1% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.62. Escalon Medical's value of 152.07% is 24427.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.62, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Escalon Medical's current Return-on-Tangible-Asset of 152.07% is 24427.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Escalon Medical and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Escalon Medical's current Return-on-Tangible-Asset is 152.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Escalon Medical stock overvalued right now?
Based on GuruFocus' analysis, Escalon Medical (ESMC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.20 — trading 33.3% above its estimated fair value. The current Return-on-Tangible-Asset is 152.07% and 24427.4% above the Medical Devices & Instruments industry median of 0.62. Escalon Medical's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Escalon Medical (ESMC), the current Return-on-Tangible-Asset is 152.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Escalon Medical (ESMC) Overvalued in 2026?
Based on GuruFocus' analysis, Escalon Medical stock appears to be overvalued.
The current stock price of $0.20 is trading 33.3% above its estimated GF Value™ of $0.15.
GuruFocus considers Escalon Medical to be Significantly Overvalued.
Key valuation signals for ESMC:
Return-on-Tangible-Asset: 152.07%
GF Value™: $0.15 vs. price of $0.20 (33.3% above fair value)
Industry Position: 24427.4% above the Medical Devices & Instruments median (#12 of 855)
No single metric tells the full story. See the ESMC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Escalon Medical Corp operates in the healthcare market, specializing in the development, manufacture, marketing, and distribution of medical devices and pharmaceuticals in the area of ophthalmology. Its products are A-Scans, B-Scans, UBM, Pachymeters, Ispan Intraocular Gases, Surgical Packs, Viscous Fluid Transfer Systems, and AXIS Image Management. Substantial revenue is generated from the domestic sales of products.
34GF Score
Get the complete analysis for ESMC
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESMC has been successfully added to your 
